Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 133


Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug.

Garofalo C, Capristo M, Manara MC, Mancarella C, Landuzzi L, Belfiore A, Lollini PL, Picci P, Scotlandi K.

PLoS One. 2013 Dec 31;8(12):e83832. doi: 10.1371/journal.pone.0083832. eCollection 2013.


Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line.

Duo J, Ma Y, Wang G, Han X, Zhang C.

DNA Cell Biol. 2013 Apr;32(4):156-64. doi: 10.1089/dna.2012.1926. Epub 2013 Mar 1.


The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.

Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ.

Cancer Res. 2009 Oct 1;69(19):7662-71. doi: 10.1158/0008-5472.CAN-09-1693. Epub 2009 Sep 29.


Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: regulation and phenotypic effects of Hypoxia-Inducible Factor.

Knowles HJ, Schaefer KL, Dirksen U, Athanasou NA.

BMC Cancer. 2010 Jul 16;10:372. doi: 10.1186/1471-2407-10-372.


Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models.

Zi FM, He JS, Li Y, Wu C, Yang L, Yang Y, Wang LJ, He DH, Zhao Y, Wu WJ, Zheng GF, Han XY, Huang H, Yi Q, Cai Z.

Cancer Lett. 2015 Jan 28;356(2 Pt B):443-53. doi: 10.1016/j.canlet.2014.09.050. Epub 2014 Oct 8.


Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.

Picarda G, Lamoureux F, Geffroy L, Delepine P, Montier T, Laud K, Tirode F, Delattre O, Heymann D, Rédini F.

Clin Cancer Res. 2010 Apr 15;16(8):2363-74. doi: 10.1158/1078-0432.CCR-09-1779. Epub 2010 Apr 6.


Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents.

Holt SV, Brookes KE, Dive C, Makin GW.

Oncol Rep. 2011 Apr;25(4):1177-81. doi: 10.3892/or.2011.1167. Epub 2011 Jan 31.


Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts.

Dickens DS, Cripe TP.

J Pediatr Hematol Oncol. 2003 Sep;25(9):709-14.


Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.

Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, Pledger WJ, Jove R.

Cancer Res. 2007 Mar 15;67(6):2800-8.


Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.

Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, Croci S, Perdichizzi S, Zambelli D, Serra M, García-Echeverría C, Hofmann F, Picci P.

Cancer Res. 2005 May 1;65(9):3868-76.


Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.

Cassinelli G, Lanzi C, Tortoreto M, Cominetti D, Petrangolini G, Favini E, Zaffaroni N, Pisano C, Penco S, Vlodavsky I, Zunino F.

Biochem Pharmacol. 2013 May 15;85(10):1424-32. doi: 10.1016/j.bcp.2013.02.023. Epub 2013 Mar 1.


Adiponectin and metformin additively attenuate IL1β-induced malignant potential of colon cancer.

Moon HS, Mantzoros CS.

Endocr Relat Cancer. 2013 Oct 24;20(6):849-59. doi: 10.1530/ERC-13-0240. Print 2013 Dec.


Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.

Ambati SR, Lopes EC, Kosugi K, Mony U, Zehir A, Shah SK, Taldone T, Moreira AL, Meyers PA, Chiosis G, Moore MA.

Mol Oncol. 2014 Mar;8(2):323-36. doi: 10.1016/j.molonc.2013.12.005. Epub 2013 Dec 15.


Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma.

Garg V, Zhang W, Gidwani P, Kim M, Kolb EA.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5446-54.


Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program.

Houghton PJ, Morton CL, Kang M, Reynolds CP, Billups CA, Favours E, Payne-Turner D, Tucker C, Smith MA.

Pediatr Blood Cancer. 2010 Dec 1;55(6):1224-6. doi: 10.1002/pbc.22355.


Antitumour effects of Yangzheng Xiaoji in human osteosarcoma: the pivotal role of focal adhesion kinase signalling.

Jiang WG, Ye L, Ji K, Ruge F, Wu Y, Gao Y, Ji J, Mason MD.

Oncol Rep. 2013 Sep;30(3):1405-13. doi: 10.3892/or.2013.2586. Epub 2013 Jul 3.


The value of adjuvant chemotherapy in the management of sarcomas in children.

Donaldson SS.

Cancer. 1985 May 1;55(9 Suppl):2184-97. Review.


Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.

Kurmasheva RT, Reynolds CP, Kang MH, Allievi C, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2014 May;61(5):922-4. doi: 10.1002/pbc.24800. Epub 2013 Oct 26.


Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma.

Cinatl J Jr, Cinatl J, Michaelis M, Kabickova H, Kotchetkov R, Vogel JU, Doerr HW, Klingebiel T, Driever PH.

Cancer Res. 2003 Apr 1;63(7):1508-14.


Metformin inhibits growth and sensitizes osteosarcoma cell lines to cisplatin through cell cycle modulation.

Quattrini I, Conti A, Pazzaglia L, Novello C, Ferrari S, Picci P, Benassi MS.

Oncol Rep. 2014 Jan;31(1):370-5. doi: 10.3892/or.2013.2862. Epub 2013 Nov 20.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk